A randomized controlled study for comprehensive treatment of proliferative allergic conjunctivitis

A Randomized Controlled Study for Comprehensive Treatment of Multicenter Proliferative Allergic Conjunctivitis

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1900022169

Enrollment

Unknown

Registered

2019-03-28

Start date

2019-07-22

Completion date

Unknown

Last updated

2019-09-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Allergic conjunctivitis

Interventions

FK506:Treatment with FK506

0.1%Flurometholone:Treatment with 0.1% Flurometholone

FK506+Azelastine Hydrochloride:Treatment with Fk506 + Azelastine eye drops

0.1%Flurometholone+Azelastine Hydrochloride:Treatment with 0.1%Flurometholone+Azelastine Hydrochloride eye drop

Eligibility

Sex/Gender

All

Age

5 Years to 69 Years

Inclusion criteria

Inclusion criteria: (1) Aged < 70 years; (2) Spring catarrhal conjunctivitis, macropapillary conjunctivitis, atopic keratoconjunctivitis; (3) Informed and agreed to participate in clinical research.

Exclusion criteria

Exclusion criteria: (1) Long-term history of hormone or immunosuppressant use; (2) Operative history of ocular trauma; (3) Systemic immune system diseases.

Design outcomes

Primary

Measure	Time frame
grading of palpebral conjunctiva papilla;grading of bulbar conjunctiva lesions;grading of cornea lesions;dry eye questionnaire;	—

Countries

China

Contacts

Public ContactJiaxu Hong

frewer@163.com+86 13917440201

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026